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The  SARS-CoV-2  pandemic  infection  has  been  reported  in
223  countries,  with  about  136  million  cases and almost  3
million  deaths  since  December  2019.1 Although  the  real
mortality  associated  with  COVID-19  remains  unknown,  the
current  global  case  fatality  reported  across  countries  ranges
from 0.2%  (in  Germany)  to  7.7%  (in Italy).2 Cardiovascular
disease,  diabetes  and  age  have  been  outlined  as  risk  factors
for  poorer  outcomes  in  COVID-19  patients.3
The  clinical  presentation  varies  widely,  from  asymp-
tomatic  or  mild  flu-like  symptoms  to  acute  severe
respiratory  distress  syndrome  and  systemic  complications
impacting  several  organs.  Cardiovascular  complications
from  COVID-19  infection  are being  reported  more  fre-
quently,  ranging  from  silent  myocardial  injury  to  throm-
boembolic  events,  acute  coronary  syndromes,  cardiogenic
shock  and  arrhythmias.4
Arrhythmias  have  been  described  in 17%  of  the  hospital-
ized  cases  and  in almost  50%  of  patients  in the  intensive
care  units  (ICU),  probably  with  a potential  contribution  to
a  higher  risk  of adverse  outcomes,  with  an  increased  risk
of  in-hospital  death.5 There  are  various  reported  series  of
different  types  of  arrhythmias,  including  bradycardia  (less
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common),  sinus  tachycardia  and  atrial  arrhythmias  (atrial
fibrillation  [AF]  and  atrial  flutter)  and  ventricular  dysrhyth-
mias,  including  cardiac  arrest.4,6
In  the study  ‘‘Cardiac  arrhythmias  in patients  pre-
senting  with  COVID-19  treated  in  Portuguese  hospitals.  A
national  registry  from Portuguese  Association  of Arrhyth-
mology,  Pacing  and  Electrophysiology’’,  published  in this
issue  of  the Journal, Dinis Mesquita  et  al.  present  the
results  of  a survey  conducted  by the Portuguese  Association
of  Arrhythmology,  Pacing  and Electrophysiology  to  assess
the  occurrence  of  arrhythmias  in COVID-19  patients  in 20
Portuguese  hospitals.7 They  report  data  from  692  hospi-
talized  patients,  with  arrhythmic  episodes  in 11.7%  of  the
cases,  including  paroxysmal  supraventricular  tachycardia,
atrial  flutter  and  AF  (the  most  common,  being recurrence
of  previously  existing  arrhythmia  in  35.9%),  bradycardia  and
ventricular  tachycardia.  Surprisingly,  none had arrhythmia-
related  complications  nor  arrhythmic  death  despite  their
elderly  age  (mean  73.5  years;  minimum  61,  maximum  80.3),
associated  comorbidities  in a  large  majority  of  the  reported
arrhythmias  (79.7%),  and  more  severe  COVID-19  disease,
with  mechanical  ventilation,  hemodynamic  instability  and
multiple  organ  failure  (in  those  patients  with  supraventric-
ular  arrhythmias)  and high  mortality  rate  (31.3%).
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Although  continuous  cardiac  rhythm  monitoring  was
obtained  only  in  the subgroup  of  393  patients  admitted  to
the  ICU  or  with  continuous  cardiac monitoring,  with  detailed
information  available  limited  to  79%  of  the  cases  with  doc-
umented  arrhythmias,  these  are useful  real  clinical  data  for
our  understanding  of  the severity  and  impact  of  arrhythmias
in  COVID-19  infection.
The  survey  also  reports  the assessment  of QT  interval  dur-
ing  hospital  admission  in 443 patients  under  therapy  with
ritonavir/lopinavir,  hydroxychloroquine  or  azithromycin.
Interestingly,  despite  medication  capable  of  QT  prolongation
in  76.6%  of the cases  with  arrhythmias,  only  seven  patients
(10.9%)  had  an increased  QTc  interval  (ranging  between  480
ms  and  596 ms).
As  pointed  out  by  the  authors,  the  availability  of  con-
tinuous  cardiac  monitoring  in only  56.8%  of  the  population
poses  strong  limitations  to  the conclusions  of the registry.
Of  course,  it seems  that  the  occurrence  of  arrhythmias
(mostly  supraventricular)  is  a common  finding,  particularly
in  patients  with  co-morbidities  and  more  severe  COVID-19
manifestations,  but  data  from  the whole  population  could
identify  clinical  variables  associated  with  higher  risk  of  new
onset  (or  reappearance)  of  arrhythmias,  and contribute  to  a
better  approach  to this  specific group  of  patients.
According  to the most  recent  literature,  risk  factors  for
the  appearance  of arrhythmias  are:  respiratory  insufficiency,
myocardial  strain  and  ischemia  or  myocarditis,  cardiogenic
shock,  sepsis  or  systemic  inflammation,  hyperactivity  of
the  sympathetic  nervous  system,  hypercoagulability  sta-
tus, electrolyte  disturbances,  and  proarrhythmic  drug  side
effects.4,6,8 Therefore,  the incidence  of arrhythmias  in
patients  with  COVID-19  is  a likely  consequence  of  systemic
illness  and  not  solely  the direct  cardiac  effect  of  the  infec-
tion.
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